Cargando…

Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress

BACKGROUND: Due to recurrent shortages of aminophylline, intravenous caffeine has emerged as a commonly used, safe and reliable method to treat adverse effects of vasodilator stress agents. We sought to evaluate the safety and effectiveness of buccal caffeine strips which are rapidly absorbed, inexp...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsadany, Mohammed, Stringer, Bryan, Bote, Josiah, Abdulla, Khaled H., Doran, Jesse A., Schwartz, Ronald G., Duvall, W. Lane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258756/
https://www.ncbi.nlm.nih.gov/pubmed/35794456
http://dx.doi.org/10.1007/s12350-022-03039-9
_version_ 1784741617939251200
author Elsadany, Mohammed
Stringer, Bryan
Bote, Josiah
Abdulla, Khaled H.
Doran, Jesse A.
Schwartz, Ronald G.
Duvall, W. Lane
author_facet Elsadany, Mohammed
Stringer, Bryan
Bote, Josiah
Abdulla, Khaled H.
Doran, Jesse A.
Schwartz, Ronald G.
Duvall, W. Lane
author_sort Elsadany, Mohammed
collection PubMed
description BACKGROUND: Due to recurrent shortages of aminophylline, intravenous caffeine has emerged as a commonly used, safe and reliable method to treat adverse effects of vasodilator stress agents. We sought to evaluate the safety and effectiveness of buccal caffeine strips which are rapidly absorbed, inexpensive, readily available, and simplify caffeine administration. METHODS: Consecutive patients undergoing regadenoson stress SPECT MPI were assessed for the occurrence of symptoms during testing over an 11-week period at a single metropolitan hospital. Adverse symptoms, including their severity and duration, were recorded at the time of testing. Patient satisfaction was rated on a scale of 1 to 5 (5 being the most satisfied). Patients received reversal with caffeine if symptoms were felt to be significant enough by the patient and physician performing the test. The treatment received alternated week to week between IV caffeine (60 mg) or 100 mg buccal caffeine strips. Caffeine was given at least 3 minutes after tracer injection. A rescue dose of IV caffeine was offered 10 minutes later if indicated. RESULTS: Of the 122 patients enrolled in the study, 70 (57%) were included during buccal caffeine weeks and 52 (43%) during IV caffeine weeks, and only 28 (24%) received reversal with a caffeine agent. Seven (6%) received IV caffeine and 21 (17%) received buccal caffeine. There was no significant difference in symptom duration between IV and buccal caffeine after treatment (152.8 vs 163.4 seconds, P = 0.87). There was no significant difference in initial and final symptom severity between groups. Only 2 patients in the buccal group required rescue IV caffeine for ongoing symptoms and emesis. None of the IV group required a rescue dose. There was no significant difference in patient satisfaction between the groups (2.8 vs 3.2, P = 0.38). CONCLUSION: Buccal caffeine strips are a safe, well tolerated, and effective initial strategy to reverse adverse effects of vasodilator stress in the minority of patients who request it. Buccal caffeine alone or with IV rescue caffeine was highly effective in reversing adverse effects and was free of major adverse clinical events. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12350-022-03039-9.
format Online
Article
Text
id pubmed-9258756
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92587562022-07-07 Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress Elsadany, Mohammed Stringer, Bryan Bote, Josiah Abdulla, Khaled H. Doran, Jesse A. Schwartz, Ronald G. Duvall, W. Lane J Nucl Cardiol Brief Report BACKGROUND: Due to recurrent shortages of aminophylline, intravenous caffeine has emerged as a commonly used, safe and reliable method to treat adverse effects of vasodilator stress agents. We sought to evaluate the safety and effectiveness of buccal caffeine strips which are rapidly absorbed, inexpensive, readily available, and simplify caffeine administration. METHODS: Consecutive patients undergoing regadenoson stress SPECT MPI were assessed for the occurrence of symptoms during testing over an 11-week period at a single metropolitan hospital. Adverse symptoms, including their severity and duration, were recorded at the time of testing. Patient satisfaction was rated on a scale of 1 to 5 (5 being the most satisfied). Patients received reversal with caffeine if symptoms were felt to be significant enough by the patient and physician performing the test. The treatment received alternated week to week between IV caffeine (60 mg) or 100 mg buccal caffeine strips. Caffeine was given at least 3 minutes after tracer injection. A rescue dose of IV caffeine was offered 10 minutes later if indicated. RESULTS: Of the 122 patients enrolled in the study, 70 (57%) were included during buccal caffeine weeks and 52 (43%) during IV caffeine weeks, and only 28 (24%) received reversal with a caffeine agent. Seven (6%) received IV caffeine and 21 (17%) received buccal caffeine. There was no significant difference in symptom duration between IV and buccal caffeine after treatment (152.8 vs 163.4 seconds, P = 0.87). There was no significant difference in initial and final symptom severity between groups. Only 2 patients in the buccal group required rescue IV caffeine for ongoing symptoms and emesis. None of the IV group required a rescue dose. There was no significant difference in patient satisfaction between the groups (2.8 vs 3.2, P = 0.38). CONCLUSION: Buccal caffeine strips are a safe, well tolerated, and effective initial strategy to reverse adverse effects of vasodilator stress in the minority of patients who request it. Buccal caffeine alone or with IV rescue caffeine was highly effective in reversing adverse effects and was free of major adverse clinical events. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12350-022-03039-9. Springer International Publishing 2022-07-06 2023 /pmc/articles/PMC9258756/ /pubmed/35794456 http://dx.doi.org/10.1007/s12350-022-03039-9 Text en © The Author(s) under exclusive licence to American Society of Nuclear Cardiology 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Brief Report
Elsadany, Mohammed
Stringer, Bryan
Bote, Josiah
Abdulla, Khaled H.
Doran, Jesse A.
Schwartz, Ronald G.
Duvall, W. Lane
Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress
title Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress
title_full Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress
title_fullStr Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress
title_full_unstemmed Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress
title_short Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress
title_sort buccal caffeine strips for reversal of adverse symptoms of vasodilator stress
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258756/
https://www.ncbi.nlm.nih.gov/pubmed/35794456
http://dx.doi.org/10.1007/s12350-022-03039-9
work_keys_str_mv AT elsadanymohammed buccalcaffeinestripsforreversalofadversesymptomsofvasodilatorstress
AT stringerbryan buccalcaffeinestripsforreversalofadversesymptomsofvasodilatorstress
AT botejosiah buccalcaffeinestripsforreversalofadversesymptomsofvasodilatorstress
AT abdullakhaledh buccalcaffeinestripsforreversalofadversesymptomsofvasodilatorstress
AT doranjessea buccalcaffeinestripsforreversalofadversesymptomsofvasodilatorstress
AT schwartzronaldg buccalcaffeinestripsforreversalofadversesymptomsofvasodilatorstress
AT duvallwlane buccalcaffeinestripsforreversalofadversesymptomsofvasodilatorstress